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The carbon footprint of pharmaceuticals through manufacturing, distribution, the incineration of unwanted 
pharmaceuticals as well as the packaging of pharmaceutical waste is an emerging and enormous challenge. 
Pharmaceuticals are major contributors to water pollution in aquatic environments that include surface 
water and groundwater. These pollutants arise not only from waste products but also from pharmaceutical 
products that have not been properly disposed of. The continuous exposure to unspecified sub-therapeutic 
doses of antibiotics presents risks to humans and other animals. Due to their extensive use and incomplete 
elimination, antibiotics have been detected in various environmental waters. The persistence of antibiotics 
in the environment and chronic exposure of organisms to these chemical stressors has also proven to 
have ecotoxicological effects. The prevailing emergence of antimicrobial resistance amongst bacteria is 
an area of primary concern, especially with regard to the release of antibiotics into the environment. 
Resistance is the acquired ability of bacterial populations to render an antibiotic ineffective as a result of 
a change in bacterial DNA which occurs when bacteria are subjected to an antibiotic concentration that 
will not kill them. A sub-lethal concentration possibly exerts a selective pressure that can result in the 
development of antimicrobial resistance in bacteria. It is clear that there is a need for extensive research 
to improve regulations and guidance on pharmaceutical waste management, pharmaceutical take-back 
programmes and consumer awareness.
Significance:
Pharmaceuticals are major contributors to water pollution in aquatic environments that include surface water 
and groundwater. This review examines the potential sources of pharmaceuticals in aquatic environments, 
their occurrence in South Africa, and public and environmental health implications posed by their presence. 
This information will provide a baseline for research and development to optimise water treatment technologies 
and to improve national, provincial, regional and municipal regulations and legislation.
Introduction
Pharmaceuticals are among the prime examples of contaminants that have recently been detected in water systems, 
with up to 90% of oral drugs that pass through the human body ending up in the water supply.1 These emerging 
pollutants, therefore, present a new global water quality challenge with potentially serious implications to human 
health and ecosystems. Some of the challenges include the development of antibiotic-resistant bacteria and 
genes2, persistence of endocrine disrupting compounds in aquatic systems, and other deleterious ecotoxicological 
effects3,4. The increased consumption, disposal and presence of human pharmaceuticals in the environment, 
particularly in aquatic systems, has raised concerns worldwide due to their continued introduction into the 
environment mainly via hospital effluents, agricultural activities and waste-water treatment plants (WWTP). 
Inadequate removal efficiencies of pharmaceuticals in WWTP leads to contamination of surface water, groundwater 
and treated drinking water.5,6 Therefore, legislative measures need to be in place to prevent and manage any 
possible risks that these compounds pose to aquatic systems. In places such as Australia, Canada, the USA and 
some European countries where preventative measures have been implemented, the regulations are stringent and 
mainly apply to controlled substances and cytotoxic drugs other than pharmaceuticals and still preclude the release 
in sewage. However, most low- and middle-income countries, including South Africa, do not have regulations 
pertaining to pharmaceutical traces as pollutants in aquatic systems. This absence has resulted in very little or no 
environmental monitoring of these chemical stressors.7
The presence of pharmaceutically active compounds at low concentrations in surface water, groundwater, 
seawater, sediments or drinking water has been reported worldwide for more than 50 years.8 The rapidly growing 
pharmaceutical industry has been pushed by the high consumption of pharmaceuticals, resulting in high frequency 
of detection of these contaminants in aquatic environments.9 Pharmaceuticals such as antibiotics, analgesics, anti-
inflammatories, hormones, non-steroidal anti-inflammatory drugs, beta-blockers, blood lipid regulators, and anti-
epileptics have been detected in aqueous environments in concentrations ranging from nanograms to micrograms 
per litre.10,11 We review the potential sources of pharmaceuticals in the aquatic environments, their occurrence in 
South Africa and public and environmental health implications posed by their presence.
Pathways of pharmaceuticals in aquatic environment
The number of pharmaceutical compounds that are prescribed for medical and veterinary use varies with region and 
country. Studies by Caldwell et al.12 and Boxall et al.13 have reported 3500 and 4000 pharmaceutical compounds, 
respectively, that are consumed globally on a daily basis. Other studies in Europe and the USA have also reported a 
daily intake of 5000 and 10 000, respectively.14,15 However, the number of pharmaceuticals and their consumption 
in developing countries such as South Africa has not been quantified. The large consumption of pharmaceuticals by 
humans and other animals provides different pathways in which pharmaceuticals can enter aquatic environments. 
Pharmaceutical substances are biologically active and hydrophilic so that the human body can take them up 
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easily. In the body, they are persistent, to avoid degradation before they 
have a curing effect. Depending on the pharmacology of a medical 
substance, it can be excreted as a mixture of metabolites, as unchanged 
substance, or conjugated with an inactivating compound attached to the 
molecule.16,17 Generally, pharmaceutical compounds are metabolised 
by the body. Although some pharmaceuticals are completely degraded 
by the body, some are partially excreted through body wastes. These 
pharmaceuticals end up in the sewage system and eventually enter 
the environment through sewage leakages or discharge of waste water 
from sewage treatment plants which deposit into the aquatic systems 
(Figure 1).18,19
The main sources of pharmaceuticals are represented by improper 
disposal of medicines at domestic sites, hospital discharges, 
aquaculture facilities, animal farming activities, municipal and industrial 
WWTPs (Figure 1).20,21 Contamination of water sources by these 
pharmaceuticals can occur via various pathways, which include surface 
run-off or leaching of human and other animal waste, and waste-
water effluent discharges.22,23 The conventional WWTPs consist of 
mechanical and chemical processes followed by biological treatment 
to remove, precipitate, and biodegrade the organic compounds based 
on their physicochemical characteristics. However, the majority of 
pharmaceuticals are not usually completely mineralised in conventional 
WWTPs equipped with primary and secondary processes.21,24 
Although tertiary treatments using technologies such as reverse 
osmosis, ultrafiltration, nanofiltration, ozonation and photolysis are 
more efficient in the removal of pharmaceuticals21,25, their application 
in developing countries such as South Africa is relatively expensive.26 
In the conventional treatment, they are either partially retained in the 
sludge, or metabolised to a more hydrophilic but still persistent form 
and, therefore, pass through the WWTP and enter surface water and 
groundwater. Their removal from waste water is variable and depends 
on the properties of the substance and process conditions such as 
sludge retention time, hydraulic retention time and temperature.27 
Levels of many pharmaceutically active compounds barely reduce in 
waste-water treatment, and therefore are detected in treated effluents. 
In addition to agricultural activities, domestic and hospital waste water 
as main sources of pharmaceutical pollutants, and poor or no sanitation 
facilities in rural African communities can contribute to pharmaceutical 
contamination of water resources, as faecal matter is washed from the 
ground into the surface water during rainy seasons.28
Pharmaceuticals in the aquatic environment of 
South Africa
Pharmaceutical compounds are released mostly unchanged or as 
metabolites mostly conjugated to polar molecules which can be easily 
re-transformed to the original active compound before being diluted by 
the large volumes of water to sub-therapeutic concentration.28 Once in 
the aqueous environment, pharmaceuticals can be distributed to various 
facets of the environment. Most pharmaceutical products have low 
volatility and therefore spread throughout the environment mixed with 
water as aqueous solutions or suspensions; some may get adsorbed onto 
soil particles and enter a food chain.29 The presence of pharmaceuticals 
in aquatic environments has been well established in developed 
countries due to their potential environmental and health impacts. 
Identified pharmaceuticals belong to the following groups: antibiotics, 
lipid regulators, beta-blockers, steroids and related hormones, cancer 
drugs, diuretics, anti-epileptics, antidepressants, tranquillisers, non-
steroidal anti-inflammatory drugs, anxiolytics, proton pump inhibitors 
and analgesics.30 These pharmaceuticals have been identified from 
environmental samples, with most being commonly used for the 
treatment of conditions related to the central nervous, cardiovascular 
and digestive systems (Table 1).31,32 Despite their wide use, relatively few 
studies have been done in Africa, including South Africa, to investigate 
the behaviour and fate of these emerging pollutants in the aquatic 
environment. In this review, we discuss the pharmaceuticals commonly 
detected in South African waters: analgesics, anti-inflammatories, 
antibiotics and antiretrovirals.
Figure 1: Sources and pathways by which pharmaceuticals may enter water resources.
3 Volume 116| Number 7/8 July/August 2020
Review Article
https://doi.org/10.17159/sajs.2020/5730
Table 1: Pharmaceuticals that have been found in aqueous ecosystems 
(adapted from Nikolaou et al.31 and Gros et al.32)
Therapeutic groups Pharmaceuticals
Cancer drugs Cyclophosphamide and ifosfamide
Diuretics Furosemide
Anti-epileptics Carbamazepine 
Antidepressants
Mianserin, fluoxetine, citalopram, venlafaxine, 
nordiazepam, oxazepam, 7-aminoflunitrazepam 
and paroxetine
Anxiolytics Alprazolam, bromazepam, oxazepam 
Tranquillisers Diazepam
Steroids and related 
hormones 
17-beta-oestradiol, oestrone, 17-alpha-ethinyloestradiol, 
diethylstilboestrol and diethylstilboestrol acetate
Beta-blockers
Metoprolol, propranolol, nadolol, atenolol, sotalol 
and betaxolol
Antibiotics
Erythromycin, ofloxacin, chlortetracyline, 
oxytetracycline, streptomycin, ciprofloxacin, 
trimethoprim, sulfamethoxazole, lincomycin, nalidixic 
acid, amoxicillin and azithromycin
Analgesics
Aspirin, ibuprofen, paracetamol, metamizole, codeine, 
indomethacin, acetaminophen, propyphenazone 
and phenazone
Non-steroidal anti-
inflammatory drugs
Diclofenac, naproxen, ketoprofen and mefenamic acid
Lipid regulators
Bezafibrate, gemfibrozil, clofibric acid, mevastatin, 
pravastatin and fenofibrate
Anti-ulcer agents Loratadine, famotidine and ranitidine
Proton pump inhibitors Lansoprazole
Analgesics and anti-inflammatory drugs
Analgesics are a class of pharmaceuticals that are used to relieve pain 
whereas anti-inflammatories are a class of drugs that are used to treat 
or reduce inflammation and swelling. Analgesics can have both anti-
inflammatory and antipyretic properties.33 The most commonly used 
analgesics and anti-inflammatories in South Africa include diclofenac, 
naproxen, ibuprofen, acetaminophen (paracetamol), aspirin and 
ketoprofen.34 Studies in South Africa have shown that ibuprofen is 
usually detected in aquatic environments in higher concentrations 
than other non-steroidal anti-inflammatory drugs. A study on the 
occurrence of selected pharmaceuticals in water and sediment of 
Umgeni River (KwaZulu-Natal, South Africa) by Matongo et al.35 reported 
concentrations of ibuprofen of up to 2.94 μg/L in effluent samples at 
the WWTP connected to the river. Their study further noted a higher 
concentration of ibuprofen (12.94 μg/L) in the effluent samples 
compared to influent samples, showing the ineffectiveness of the WWTP 
in removing ibuprofen.35 Therefore the receiving river could potentially be 
contaminated over time. Another study in the same province monitored 
naproxen, ibuprofen and diclofenac in a river and WWTP located around 
the city of Durban (KwaZulu-Natal, South Africa). In that study, maximum 
concentrations of 6.84 μg/L, 19.2 μg/L and 9.69 μg/L were reported 
for naproxen, ibuprofen and diclofenac, respectively. The corresponding 
maximum concentrations detected in WWTP effluent samples for 
naproxen, ibuprofen and diclofenac were 14.4 μg/L, 67.9 μg/L and 
23.5 μg/L, respectively.36 A maximum concentration of 221 μg/L was 
recorded in the same study from a WWTP influent sample. A study in the 
North West Province reported a maximum concentration of 13.7 μg/L for 
ibuprofen in effluent samples at a WWTP.37 In surface water, the highest 
concentration of ibuprofen (62.0 μg/L) was detected in KwaZulu-Natal at 
the point where a tributary, Msunduzi, joins the Umgeni River (Table 2).36 
Antibiotics
Antibiotics are chemical entities constituting an integral part of modern 
medicine and are an essential line of defence against pathogenic bacteria 
and fungi by eradicating or inhibiting their growth. Approximately 
200 000 tonnes of antibiotics are produced every year, worldwide.38,39 
Although antibiotics are useful, their overuse, inappropriate use and 
unregulated use have contributed to the presence of their metabolites and 
residues in the environment. Based on their biological and physicochemical 
properties, antibiotics can persist for extended periods of time in the 
environment, where they can contaminate water sources.40 There has 
been increasing concern over the past two decades about pollution of 
water sources by antibiotics, with several studies focusing on WWTP 
effluent discharges as potential hotspots of contamination.41,42 A huge 
proportion of antibiotics that are ingested end up in waste water and 
are amongst the most detected pharmaceuticals in WWTPs around the 
world.43 They are classified as recalcitrant bio-accumulative environmental 
pollutants, with the rate of degradation of most of these compounds such 
that it cannot offset their accumulation.44 Most antibiotics prescribed and 
dispensed cause side effects which differ in severity according to the agent 
used; however, in most cases, these side effects are outweighed by the 
therapeutic benefits and are therefore overlooked during chemotherapy. 
The major concern about the presence of antibiotics in the environment 
is the proliferation of antimicrobial resistance genes and antimicrobial 
resistance bacteria, which reduce the therapeutic potential against human 
and non-human animal bacterial pathogens.43
Several antibiotics have been reported in environmental waters due to 
their extensive use in humans and other animals to treat infections. 
The global increase in the use of these antibiotics has been observed in 
low- and middle-income countries, including South Africa, where there 
is a high incidence of diseases such as cholera, typhoid, meningitis, 
gonorrhoea, tuberculosis (TB) and malaria that are associated with 
drug-resistant pathogens.45,46 In addition, other factors such as the 
discharge of untreated waste, the low cost of individual antibiotics, 
the discharge through urine and faeces of animals and the lack of drug 
return programmes have been cited as contributors to the presence 
of antibiotics in most African waters.46 The occurrence of antibiotics 
in South African waters has been investigated in WWTPs as well 
as in surface waters.35,47,48,49 Among the investigated antibiotics in 
South African aquatic systems, a high concentration of sulfamethoxazole 
(59.28 μg/L) was detected at the influent of the WWTP of the Northern 
water works in Durban.35 A study by Agunbiade and Moodley50 detected 
ciprofloxacin at concentrations of 27 μg/L and 14 μg/L in the influent 
and effluent of a WWTP in KwaZulu-Natal. However, no ciprofloxacin 
has been reported in South African surface waters (Table 2). A more 
recent study to determine the concentrations of antibiotics and other 
pharmaceuticals at two hospital WWTPs in the North West Province 
reported a maximum of 45.38 μg/L and 3.22 μg/L in influent and 
effluent samples, respectively, for tetracycline.37 Other pharmaceuticals 
– namely azithromycin, ofloxacin, norfloxacin and erythromycin – have 
also been detected in WWTPs, but in lower concentrations (<10 μg/L 
or 10 ng/L).35,48,49,51,52 To date, there are no studies that have reported 
the occurrence of antibiotics in potable drinking water in South Africa.
Antiretroviral drugs 
Antiretroviral (ARV) treatment comprises a combination of nucleoside 
reverse transcriptase inhibitors, non-nucleoside reverse transcriptase 
inhibitors and protease inhibitors that act to inhibit multiple, viral targets 
and approved integrase inhibitors in patients with viral resistance, usually 
people with HIV. A combination of drugs is also used to prevent mother-
to-child transmission.52 In South Africa, at least 6.2 million people 
are HIV positive, according to statistics released in 2016.53 From that 
number, half of these individuals are enrolled for ARV therapy, with the 
number increasing every year.54 A study by Schoeman et al.55 estimated 
that around 162 883 kg of ARV drugs could reach the aquatic systems 
in South Africa, based on high consumption figures of 2 500 000 and 
2 150 880 people on ARV therapy in 2011 and 2012, respectively.56
The detection of ARV drugs in water resources of South Africa has been 
reported for the provinces of KwaZulu-Natal57,58, Gauteng59 and the Western 
Cape60. The ARV drugs abacavir, atazanavir, darunavir, didanosine, efavirenz, 
emtricitabine, indinavir, lamivudine, lopinavir, maraviroc, nevirapine, 
raltegravir, ritonavir, saquinavir, tenofovir, zalcitabine and zidovudine have 
been reported in South African aquatic environments. Among ARV drugs, 
emtricitabine has been detected at the highest concentration of 172 μg/L 
in influent samples of a WWTP in the Western Cape.60 Low concentrations 
of up to 0.013 μg/L were reported for emtricitabine in a separate study in 
surface water samples. In South African aquatic environments, the most 
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prevalent ARV drug detected has been efavirenz, which has been detected 
in Durban WWTP influent samples at high concentrations of up to 140 μg/L 
(Table 2).58 Low concentrations of efavirenz, ranging between 0.002 μg/L 
and 2.45 μg/L, have been reported in surface waters.58,61 Zidovudine and 
darunavir have also been detected at relatively high concentrations (53 μg/L 
and 43 μg/L, respectively) in the influent samples of WWTPs in KwaZulu-
Natal (Table 2).57
Table 2: Maximum concentrations for pharmaceuticals quantified in 
South African water bodies
Pharmaceuticals
Maximum concentration 
(mg/L)
References
WWTP 
Influent
WWTP 
Effluent
Surface 
water
Analgesics and anti-inflammatories
Ibuprofen 221 67.9 62.0
Kanama et al.37; 
Madikizela and 
Chimuka36
Naproxen 109.3 14.4 6.8
Madikizela and 
Chimuka36
Diclofenac 115.1 23.5 9.7
Madikizela and 
Chimuka36
Fenoprofen 80 47 Madikizela et al.34
Antibiotics
Sulfamethoxazole 59.28 0.0803 6.01
Matongo et al.35; 
Nyamukamba et al.49
Ciprofloxacin 27 14
Agunbiade and 
Moodley50
Tetracycline 45.38 3.22 Kanama et al.37
Antiretroviral drugs
Emtricitabine 172 41.7 0.013
Mosekiemang et al.60; 
Rimayi et al.61
Efavirenz 140 93.1 2.45 Mtolo et al.58
Zidovudine 53 0.5 Abafe et al.57
Darunavir 43 17 Abafe et al.57
WWTP, waste-water treatment plant
Impacts of pharmaceuticals in aquatic systems
Assessment of the environmental risk posed by pharmaceuticals and 
their metabolites has become a major focus in recent years because of 
their continuous introduction into aquatic systems. In the South African 
context, the fact that the country is classified as a water scarce 
country, makes the situation even more critical as there are relatively 
few water resources. Although pharmaceuticals may be present in 
aquatic environments in low concentrations, their extensive use, high 
reactivity with biological systems, continuous release and relatively low 
degradation makes them pseudo-persistent in aquatic environments. 
The potential effects to the environment and public health are chronic 
rather than acutely toxic, and depend on exposure, that is, bioavailability, 
susceptibility to the compound in question, and the degradability of the 
compound.62 Globally, relatively few studies have focused on determining 
the toxicity of pharmaceuticals in the environment, putting humans and 
other animals at risk as there is a lack of information on the potential 
toxicity of these biologically active compounds.10 
South Africa has been battling with epidemics of both TB and HIV/Aids 
over the last two decades. The country has the third worst TB epidemic 
worldwide (after China and India) and is among the six countries 
that account for 60% of the global TB burden. South Africa has the 
highest burden of the disease in Africa, with an estimated incidence of 
454 000 cases, at a rate of 834 cases per 100 000 population as reported 
in 2015.63 Prevalence of HIV is the highest in the world, with 12.7% of the 
population in 2016 reported to be infected.63 In addition, South Africa 
reported the highest number of HIV-associated TB cases worldwide, with 
59.9% of TB patients co-infected with HIV in 2017. Furthermore, patients 
co-infected with TB and HIV have increased susceptibility to other 
infections such as Pneumocystis pneumonia.64 The prevalence of these 
two epidemics in South Africa means that tonnes of pharmaceuticals 
(ARV, antitubercular and antimicrobial drugs) are consumed to control 
the two epidemics. This presents a new problem concerning the presence 
and fate of these drugs in the aquatic environment. Pharmaceuticals can 
therefore pose potential environmental and public health issues that are 
of importance to South Africa.
Environmental impacts
Pharmaceuticals are designed to interfere with specific metabolic, 
enzymatic, or cell-signalling mechanisms at low concentrations through 
a specific mode of action in humans. The persistence of pharmaceuticals 
in the environment and chronic exposure to these chemical stressors can 
have ecotoxicological effects on non-target organisms.62,65 The nature of 
the aqueous environment, together with the physicochemical properties 
of the pharmaceuticals, also play an important role as they determine 
whether the pharmaceuticals will succumb to the processes (including 
the employed treatment) or persist in the environment.66 For example, 
fluoroquinolones, sulfonamides, trimethoprim and cephalosporins 
are resistant to microbial biodegradation and tend to persist in WWTP 
and other environmental compartments.67 Fluoroquinolones also have 
strong adsorptive properties and tend to accumulate on sediments and 
other organic matter thus elevating their persistence in environmental 
matrices.65 In addition, the presence of antimicrobial compounds in the 
waste water at particular levels can reduce and/or inhibit the growth of 
sludge bacteria that are involved in biotransforming drugs and degrading 
organic matter. This inhibition can decrease the efficiency of the WWTP 
and may result in contamination of receiving water bodies.68
Toxicity studies of fish, daphnia and algae have been used to 
predict environmental concentrations and ecological risk of most 
pharmaceuticals.67,69 The biological activity of pharmaceuticals released 
in aquatic systems has been observed in nature and laboratory 
investigations have shown that they cause both acute and chronic 
effects. For example, the antibiotics clarithromycin sulfamethoxazole, 
ofloxacin, lincomycin, enrofloxacin and ciprofloxacin have been reported 
to be toxic to freshwater algae.20 Low concentrations (in nanograms/
litre) of the synthetic oestrogen 17-alpha-ethinyloestradiol often used 
in contraceptive pills have been shown to enlarge fish livers and affect 
the sexual characteristics of male fish in surface water. The anti-
inflammatory drug diclofenac also seems to be cause for concern 
for aquatic organisms.70 A study done by Fent et al.71 reported that 
diclofenac was associated with the disappearance of the Orient white-
backed vulture in India and Pakistan. In mammals, diclofenac has 
been reported to affect the liver and kidneys. Furthermore, propranolol 
(a beta-blocker) detected in northeastern Spain was reported to have 
toxic effects on zooplankton and benthic organisms. 
Public health impacts
Drinking water and consumption of aquatic organisms are two ways 
in which humans can be exposed to pharmaceuticals that pollute the 
aquatic environment. Therefore, possible risks of exposure for human 
health are a subject of concern, especially for the countries that use 
surface water as their main source of drinking water. Several quantitative 
pharmaceutical risk assessment studies on exposure to trace levels of 
pharmaceuticals in drinking water, conducted in different parts of the 
world, have shown very low risks to human health based on toxicological 
data.72,73 However, these studies do not rule out possible effects on 
human health as some studies are often been based on limited sets of 
monitoring data which do not consider long-term effects of exposure 
and have limited knowledge on the mixed effects of pharmaceuticals 
in drinking water consumed by humans.73 In addition, some studies 
focus on pharmaceutical concentrations in surface water only, and not 
drinking water, to assess human health risk, assuming that drinking 
water treatment plants do not remove any of the pharmaceuticals.74,75 
In addition to introducing toxins to drinking water, the development of 
resistance to antimicrobial compounds is another risk that pharmaceuticals 
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in aquatic environments can pose to public health. The overuse and misuse 
of antibiotics may cause a risk to human health by promoting antibiotic-
resistant bacteria and antibiotic resistance genes in aquatic environments.2,5 
This occurs as a result of the high selective pressure imposed by antibiotics 
on bacteria. The bacterial community that can withstand this antimicrobial 
pressure will survive and multiply, leading to more resistant strains in 
the aquatic environments.76 The resistant genes can be horizontally 
transferred from animal to human pathogens and also across different 
classes of antibiotics used in veterinary and medical contexts, especially 
when the antibiotics have the same mechanism of action.38 Horizontal 
gene transfer is a mechanism by which bacteria can disseminate novel 
traits, including acquired antimicrobial resistance. It is usually carried out 
by mobile DNA elements such as plasmids, transposons and integrons.77 
When bacteria acquire resistance genes to protect them against various 
antibiotics, they are capable of employing several biochemical types of 
resistance mechanisms such as antibiotic inactivation, target modification, 
alteration in permeability and bypass metabolic pathway.78 Inadequate 
management of waste water may therefore release antibiotics, antibiotic-
resistant bacteria and antibiotic resistance genes into the environment, 
thus presenting a potential environmental health risk. Antibiotic resistance 
is a major health concern; the presence of antibiotics in treated waste 
water is increasing and will lead to higher mortality and morbidity as 
untreatable infectious diseases increase.70
Antimicrobial resistance has become a great challenge in clinical therapy 
mainly because it compromises the effectiveness of antibiotics, resulting 
in therapeutic failure, elevated health costs, and increased morbidity and 
mortality rates.79 For example, pathogens such as multidrug resistant 
Klebsiella pnemoniae cannot be treated with any antibiotic currently on 
the market.76
Research gaps and future perspectives in 
South Africa
The presence, persistence and toxicity of pharmaceuticals in the aquatic 
environment is an important subject that needs to be extensively 
investigated to help prevent effects on the environment and human health. 
There is a lack of baseline studies in South Africa to counter any effects 
that can be caused by the presence of pharmaceuticals in South African 
water systems. South Africa has particular challenges, such as a high 
burden of HIV/Aids and TB, with resistant strains of TB prevalent in 
the population. This points to a high use of ARV drugs and antibiotics, 
resulting in relatively high concentrations being released into aquatic 
environments. Therefore, there is a need to quantify and determine their 
fate, and extrapolate their possible long-term effects on the environment 
and public health. There have been few studies conducted in South Africa 
on pharmaceutical drugs in water and their biodegradation profile, even 
though South Africa has an estimated 7.7 million people living with 
HIV, of which 62% of all people living with HIV in South Africa are on 
ARV treatment. Therefore, it is expected that the concentration of ARV 
drugs will be considerably high in waste water and surface water. This 
can be determined by comprehensive quantitative pharmaceutical risk 
assessments that are unique to the needs of South Africa. These studies 
will help to analyse different aspects of pharmaceutical exposure to the 
environment and humans, and the toxicity and associated health risks.
Removal of pharmaceuticals by WWTPs is important in reducing disposal 
to aquatic environments Currently, treatment processes in South Africa 
cannot remove pharmaceuticals completely, resulting in their discharge 
into water bodies. There is a need for research to determine how 
these sewage treatments are efficient in removing different types of 
pharmaceuticals. This can also be applied to drinking water plants that 
use potentially contaminated surface water as their source. This will help 
redesign treatment plants that can exhaustively remove pharmaceuticals 
that can be toxic or harmful to the environment and humans. Most 
quantitative pharmaceutical risk assessments have focused on urban 
areas, neglecting the rural populations that often utilise unpurified water 
for drinking. Therefore, studies in rural areas in South Africa will provide 
relevant information on the occurrence and fate of pharmaceuticals in 
the environment that can be compared to studies in urban areas. Not 
only do these pharmaceuticals negatively affect human life but they 
also affect aquatic life negatively. Several studies suggest diverse 
negative effects on aquatic life that are exposed to these trace amounts 
of pharmaceuticals in their habitats. South Africa is a semi-arid area, 
and pharmaceutical remains are especially harmful to aquatic life during 
drought, because the concentration automatically becomes higher due 
to low volumes of water.
Waste management is a pressing issue in South Africa, and improper 
dumping of dangerous health-care waste is a serious concern. The groups 
that are responsible for this misconception are nurses, pharmacists 
and other health-care professionals. It also places an unacceptably 
high financial and human resources burden on health authorities to 
manage the problem. Health-care waste entering the normal domestic 
waste stream will end up being disposed of in municipal landfill sites. 
When health-care waste is placed in landfills or buried, contamination of 
groundwater may occur and may result in the spread of Escherichia coli.
If landfills are insecure, expired drugs may come into contact with 
children and scavenging animals. Evidence suggests that the presence of 
antibiotics in waste water may be contributing to antibiotic resistance, and 
if these antibiotics are present in waste water for a longer period, they may 
cause genetic effects in humans and marine life. It is therefore essential 
that health-care facilities dispose of all waste in accordance with national, 
provincial, regional and municipal regulations and legislation. Hence, it is 
essential to raise public awareness and encourage consumers to adopt 
proper disposal practices for unwanted pharmaceuticals.
Conclusion
Pharmaceuticals are used in human and veterinary medicines, 
aquaculture, animal husbandry, and also in agriculture for the treatment 
of diseases. The uptake and excretion of these pharmaceuticals pose a 
risk for the contamination of aquatic systems. This is a good reason for 
intensive research into the fate of pharmaceuticals, which covers their 
detection, distribution, transformation, and impact on microorganisms 
in the surrounding environment, the development of resistance of 
microorganisms to pharmaceuticals, and the possible harmful effects 
on the treatment of animal and human bacterial disease. In addition, 
there should also be continued research and development to optimise 
water treatment technologies and to improve national, provincial, 
regional and municipal regulations and legislation. There is a need for 
cooperation of stakeholders, manufacturers, regulators, veterinarians, 
pharmacists and consumers to agree on ways to decrease the harmful 
levels of pharmaceuticals in the environment. It is also important that 
the pharmaceutical industry be responsible for the development and 
implementation of pollution control measures and monitoring thereof.
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